Biosidus S.A.U.

About Biosidus S.A.U.

Biosidus is a engaged in the development, manufacturing and commercialization of high-quality recombinant proteins.  Since the launch of Erythropoetin in 1990, Biosidus has successively marketed the following biosimilars: Interferon Alfa 2a, Interferon Alfa 2b, Filgrastim, Somatropin, Lenograstim, Azacitidine, Bortezomib, Interferon beta 1a (SC and IM) and Teriparatide. Today, these products are being commercialized in more than 50 markets.  
With headquarters and manufacturing plants located in Buenos Aires, Argentina, we have developed regional hubs in order to intensify our presence in emerging markets: 1) LATAM, with presence in Mexico DF covering Mexico and Central America and in Bogota, covering Colombia and the Andean markets; 2) AFRICA, MIDDLE EAST and EUROPE, with presence in Barcelona and Dubai; 3) ASIA, with presence in Bangkok, covering SEA markets.  
Additionally, we have two biosimilars in advanced development stage:      a.    Pegfilgrastim  b. &n...

  • AR
  • 2015
    On CPHI since
  • 2
    Certificates
  • 500 - 999
    Employees
Company types
Biopharmaceutical company
Generics/Biosimilars Manufacturer
Primary activities
Biopharmaceutical
Contact info
Meet us at

CPHI Frankfurt 2022

Messe Frankfurt, Germany
1-3 November 2022

Products from Biosidus S.A.U. (5)

Biosidus S.A.U. Resources (2)